カテゴリー： 世界, 医療/バイオ, Grand View Research

世界の子宮筋腫治療薬市場2023-2030：薬物クラス別（GnRH作動薬、GnRH拮抗薬）、種類別（粘膜下筋腫、硬膜内筋腫）、エンドユーザー別

【英語タイトル】Uterine Fibroid Treatment Drugs Market Size, Share & Trends Analysis Report By Drug Class (GnRH Agonists, GnRH Antagonists), By Type (Submucosal Fibroids, Intramural Fibroids), By End-user, And Segment Forecasts, 2023 - 2030

Grand View Researchが出版した調査資料（GRV23JUN103）・商品コード：GRV23JUN103
・発行会社（調査会社）：Grand View Research
・発行日：2023年5月10日
・ページ数：130
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後3営業日）
・調査対象地域：グローバル
・産業分野：医薬品
◆販売価格オプション（消費税別）
Single UserUSD5,950 ⇒換算￥892,500見積依頼/購入/質問フォーム
Multi User/Five UserUSD6,950 ⇒換算￥1,042,500見積依頼/購入/質問フォーム
Global/corporate LicenseUSD8,950 ⇒換算￥1,342,500見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

Grand View Research社の市場調査書によると、世界の子宮筋腫治療薬市場規模が、予測期間中（2023年～2030年）に年平均10.2％増加し、2030年までに39.1億ドルへ達すると見込まれています。本調査書では、子宮筋腫治療薬の世界市場を調査対象とし、調査手法・範囲、エグゼクティブサマリー、市場変動・動向・範囲、薬物クラス別（性腺刺激ホルモン放出ホルモン（GnRH ）作動薬、性腺刺激ホルモン放出ホルモン（GnRH ）拮抗薬、プロゲスチン放出型子宮内避妊器具（lud）・避妊薬、非ホルモン剤、その他）分析、種類別（漿膜下筋腫、硬膜内筋腫、粘膜下筋腫、脚状筋腫）分析、エンドユーザー別（病院薬局、小売薬局、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などについて調査・分析し、まとめています。なお、こちらに掲載されている企業情報には、Myovant Sciences Gmbh、Pfizer Inc.、Abbvie, Inc.、Ferring B.V.、Astrazeneca、Bayer Ag、Amring Pharmaceuticals Inc.、Watson Pharma, Inc.などが含まれています。
・調査手法・範囲
・エグゼクティブサマリー
・市場変動・動向・範囲
・世界子宮筋腫治療薬の市場規模：薬物クラス別
- 性腺刺激ホルモン放出ホルモン（GnRH ）作動薬の市場規模
- 性腺刺激ホルモン放出ホルモン（GnRH ）拮抗薬の市場規模
- プロゲスチン放出型子宮内避妊器具（lud）・避妊薬の市場規模
- 非ホルモン剤の市場規模
- その他子宮筋腫治療薬の市場規模
・世界子宮筋腫治療薬の市場規模：種類別
- 漿膜下筋腫における市場規模
- 硬膜内筋腫における市場規模
- 粘膜下筋腫における市場規模
- 脚状筋腫における市場規模
・世界子宮筋腫治療薬の市場規模：エンドユーザー別
- 病院薬局における市場規模
- 小売薬局における市場規模
- その他エンドユーザーにおける市場規模
・世界子宮筋腫治療薬の市場規模：地域別
- 北米の子宮筋腫治療薬市場規模
- ヨーロッパの子宮筋腫治療薬市場規模
- アジア太平洋の子宮筋腫治療薬市場規模
- 中南米の子宮筋腫治療薬市場規模
- 中東・アフリカの子宮筋腫治療薬市場規模
・競争状況

子宮筋腫治療薬市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界の子宮筋腫治療薬市場規模は2022年から2030年にかけて年平均成長率10.2%で拡大し、2030年には39.1億ドルに達すると予測されています。同市場の成長は、子宮筋腫（UF）の有病率の上昇と、女性の月経多量出血を減少させる新薬の有効性の増加に起因しています。IntechOpenに掲載された論文によると、月経多量出血は子宮筋腫の一般的な症状で、年間約140万人の女性が罹患しています。また、60％近くの女性が、症状が身体活動を妨げ、生活の質に影響を及ぼすと報告しています。さらに、24％の女性が、症状のために仕事で能力を十分に発揮できないと報告しています。

したがって、高度な作用機序を有し、臨床効果が高く、副作用の少ない新薬に対する需要の高まりが、市場を牽引すると予想されます。加えて、研究活動への資金提供の増加が市場の成長を後押しすると予想されます。例えば、Society for Women’s Health Research（SWHR）は、2021年のStephanie Tubbs Jones子宮筋腫研究教育法の更新と再提案を支持しました。この法律は、研究のための資金調達を進め、この疾患に関する教育を強化することを目的としています。子宮筋腫に伴う大量出血の治療薬として、複数のゴナドトロピン放出ホルモン（GnRH）拮抗薬が最近承認されたことも市場を牽引するでしょう。例えば、2020年5月、米国FDAは子宮筋腫の治療薬としてオリアホンを承認しました。

それは閉経前女性の大量出血の治療薬として承認された初めての経口薬となりました。治療期間は24ヵ月で、小売価格は56錠1,100米ドルです。さらに、主要企業はより高い市場シェアを獲得するため、新規上市、M&A、事業拡大、提携に注力しています。例えば、キッセイ薬品工業株式会社は2022年6月、子宮筋腫治療薬リンザゴリックスの第III相臨床試験を日本で開始すると発表しました。同剤はすでに欧州では「イゼルティ」の商品名でEMAの承認を受けています。開発元であるObsEva社は、2022年2月に本剤の地域販売権をTheramex社に売却しました。この契約により、セラメックス社は欧州、ブラジル、オーストラリアでの販売権を獲得しました。

子宮筋腫治療薬市場レポートハイライト

– GnRH拮抗薬セグメントは予測期間中に最も速い成長率を記録するとみられています。

– 2020年5月に米国でOriahnn、2021年5月に米国でMyfembree、2022年6月に欧州でYseltyが承認されるなど、複数の薬剤が最近承認されたことが市場成長の原動力になると予測されます。

– 2022年の子宮筋腫治療薬市場は粘膜下筋腫分野がシェアの大半を占めました。

– 2022年の子宮筋腫治療薬市場は、薬の入手のしやすさから小売薬局が支配的でした。

– 北米は、大手企業の存在、健康状態の高い有病率、薬の入手可能性に関する患者の意識の高まりなど、さまざまな要因により、2022年の世界市場で最大のシェアを占めました。

グローバル市場調査レポート販売サイトのwww.marketreport.jpです。

❖ レポートの目次 ❖

Table of Contents

Chapter 1 Methodology and Scope
1.1 Market Segmentation and Scope
1.1.1 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Gvr’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach: Commodity Flow Approach
1.7 Research Assumptions
1.8 List of Secondary Sources
1.9 List of Abbreviations
1.10 Objectives
1.10.1 Objective 1
1.10.2 Objective 2
1.10.3 Objective 3
1.10.4 Objective 4
Chapter 2 Executive Summary
2.1 Market Snapshot
2.2 Segment Snapshot
2.3 Segment Snapshot
2.4 Competitive Landscape Snapshot
Chapter 3 Uterine Fibroid Treatment Drugs Market Variables, Trends, & Scope
3.1 Uterine Fibroid Treatment Drugs Market Lineage Outlook
3.1.1 Parent Market Outlook
3.1.2 Ancillary Market Outlook Market
3.2 Market Dynamics
3.2.1 Market Driver Impact Analysis
3.2.1.1 Rising Prevalence Of Uterine Fibroids
3.2.1.2 Effectiveness Of Novel Drugs In Reducing Heavy Menstrual Bleeding In Women With Uterine Fibroids
3.2.2 Market Restraint Analysis
3.2.2.1 Availability Of Generic Drugs In The Market
3.3 Industry Analysis Tools
3.3.1 Porter’s Analysis
3.3.2 Macroeconomic Analysis
Chapter 4 Uterine Fibroid Treatment Drugs Market – Segment Analysis, by Drug Class, 2018 – 2030 (USD Million)
4.1 Uterine Fibroid Treatment Drugs Market: Drug Class Movement Analysis
4.2 Uterine Fibroid Treatment Drugs Market Estimates & Forecast, by Drug Class (USD Million)
4.2.1 Gonadotropin-Releasing Hormone (Gnrh) Agonists
4.2.2 Gonadotropin-Releasing Hormone (Gnrh) Antagonists
4.2.3 Progestin-Releasing Intrauterine Device (Iud) & Contraceptives
4.2.4 Non-Hormonal Medications
4.2.5 Others
Chapter 5 Uterine Fibroid Treatment Drugs Market – Segment Analysis, By Type, 2018 – 2030 (USD Million)
5.1 Uterine Fibroid Treatment Drugs Market: Type Movement Analysis
5.2 Uterine Fibroid Treatment Drugs Market Estimates & Forecast, By Type(USD Million)
5.2.1 Subserosal Fibroids
5.2.2 Intramural Fibroids
5.2.3 Submucosal Fibroids
5.2.4 Pedunculated Fibroids
Chapter 6 Uterine Fibroid Treatment Drugs Market – Segment Analysis, By End-User, 2018 – 2030 (USD Million)
6.1 Uterine Fibroid Treatment Drugs Market: End-User Movement Analysis
6.2 Uterine Fibroid Treatment Drugs Market Estimates & Forecast, By End-User (USD Million)
6.2.1 Hospital Pharmacies
6.2.1 Retail Pharmacies
6.2.3 Others
Chapter 7 Uterine Fibroid Treatment Drugs Market: Regional Estimates and Trend Analysis, By Treatment, By Type, and By End User
7.1 Uterine Fibroid Treatment Drugs Market: Regional Outlook
7.2 North America
7.2.1 North America Uterine Fibroid Treatment Drugs Market Estimates And Forecasts, 2018 – 2030 (USD Million)
7.2.2 U.S.
7.2.2.1 Key Country Dynamics
7.2.2.2 U.S. Uterine Fibroid Treatment Drugs Market Estimates & Forecasts And Trend Analysis, 2018 – 2030 (USD Million)
7.2.2.3 Target Disease Incidence
7.2.2.5 Competitive Scenario
7.2.2.6 Regulatory Framework
7.2.2.7 Reimbursement Scenario
7.2.3 Canada
7.2.3.1 Key Country Dynamics
7.2.3.2 Canada Uterine Fibroid Treatment Drugs Market Estimates & Forecasts And Trend Analysis, 2018 – 2030 (USD Million)
7.2.3.3 Target Disease Incidence
7.2.3.4 Competitive Scenario
7.2.3.5 Regulatory Framework
7.2.3.6 Reimbursement Scenario
7.3 Europe
7.3.1 Europe Uterine Fibroid Treatment Drugs Market Estimates And Forecasts, 2018 – 2030 (USD Million)
7.3.2 Uk
7.3.2.1 Key Country Dynamics
7.3.2.2 Uk Uterine Fibroid Treatment Drugs Market Estimates & Forecasts And Trend Analysis, 2018 – 2030 (USD Million)
7.3.2.3 Target Disease Incidence
7.3.2.4 Competitive Scenario
7.3.2.5 Regulatory Framework
7.3.2.6 Reimbursement Scenario
7.3.3 Germany
7.3.3.1 Key Country Dynamics
7.3.3.2 Germany Uterine Fibroid Treatment Drugs Market Estimates & Forecasts And Trend Analysis, 2018 – 2030 (USD Million)
7.3.3.3 Target Disease Incidence
7.3.3.4 Competitive Scenario
7.3.3.5 Regulatory Framework
7.3.3.6 Reimbursement Scenario
7.3.4 France
7.3.4.1 Key Country Dynamics
7.3.4.2 France Uterine Fibroid Treatment Drugs Market Estimates & Forecasts And Trend Analysis, 2018 – 2030 (USD Million)
7.3.4.3 Target Disease Incidence
7.3.4.4 Competitive Scenario
7.3.4.5 Regulatory Framework
7.3.4.6 Reimbursement Scenario
7.3.5 Italy
7.3.5.1 Key Country Dynamics
7.3.5.2 Italy Uterine Fibroid Treatment Drugs Market Estimates & Forecasts And Trend Analysis, 2018 – 2030 (USD Million)
7.3.5.3 Target Disease Incidence
7.3.5.4 Competitive Scenario
7.3.5.5 Regulatory Framework
7.3.5.6 Reimbursement Scenario
7.3.6 Spain
7.3.6.1 Key Country Dynamics
7.3.6.2 Spain Uterine Fibroid Treatment Drugs Market Estimates & Forecasts And Trend Analysis, 2018 – 2030 (USD Million)
7.3.6.3 Target Disease Incidence
7.3.6.4 Competitive Scenario
7.3.6.5 Regulatory Framework
7.3.6.6 Reimbursement Scenario
7.3.7 Denmark
7.3.7.1 Key Country Dynamics
7.3.7.2 Denmark Uterine Fibroid Treatment Drugs Market Estimates & Forecasts And Trend Analysis, 2018 – 2030 (USD Million)
7.3.7.3 Target Disease Incidence
7.3.7.4 Competitive Scenario
7.3.7.5 Regulatory Framework
7.3.7.6 Reimbursement Scenario
7.3.8 Sweden
7.3.8.1 Key Country Dynamics
7.3.8.2 Sweden Uterine Fibroid Treatment Drugs Market Estimates & Forecasts And Trend Analysis, 2018 – 2030 (USD Million)
7.3.8.3 Target Disease Incidence
7.3.8.4 Competitive Scenario
7.3.8.5 Regulatory Framework
7.3.8.6 Reimbursement Scenario
7.3.9 Norway
7.3.9.1 Key Country Dynamics
7.3.9.2 Norway Uterine Fibroid Treatment Drugs Market Estimates & Forecasts And Trend Analysis, 2018 – 2030 (USD Million)
7.3.9.3 Target Disease Incidence
7.3.9.4 Competitive Scenario
7.3.9.5 Regulatory Framework
7.3.9.6 Reimbursement Scenario
7.4 Asia Pacific
7.4.1 Asia Pacific Uterine Fibroid Treatment Drugs Market Estimates And Forecasts, 2018 – 2030 (USD Million)
7.4.2 Japan
7.4.2.1 Key Country Dynamics
7.4.2.2 Japan Uterine Fibroid Treatment Drugs Market Estimates & Forecasts And Trend Analysis, 2018 – 2030 (USD Million)
7.4.2.3 Target Disease Incidence
7.4.2.4 Competitive Scenario
7.4.2.5 Regulatory Framework
7.4.2.6 Reimbursement Scenario
7.4.3 China
7.4.3.1 Key Country Dynamics
7.4.3.2 China Uterine Fibroid Treatment Drugs Market Estimates & Forecasts And Trend Analysis, 2018 – 2030 (USD Million)
7.4.3.3 Target Disease Incidence
7.4.3.4 Competitive Scenario
7.4.3.5 Regulatory Framework
7.4.3.6 Reimbursement Scenario
7.4.4 India
7.4.4.1 Key Country Dynamics
7.4.4.2 India Uterine Fibroid Treatment Drugs Market Estimates & Forecasts And Trend Analysis, 2018 – 2030 (USD Million)
7.4.4.3 Target Disease Incidence
7.4.4.4 Competitive Scenario
7.4.4.5 Regulatory Framework
7.4.4.6 Reimbursement Scenario
7.4.5 Australia
7.4.5.1 Key Country Dynamics
7.4.5.2 Australia Uterine Fibroid Treatment Drugs Market Estimates & Forecasts And Trend Analysis, 2018 – 2030 (USD Million)
7.4.5.3 Target Disease Incidence
7.4.5.4 Competitive Scenario
7.4.5.5 Regulatory Framework
7.4.5.6 Reimbursement Scenario
7.4.6 South Korea
7.4.6.1 Key Country Dynamics
7.4.6.2 South Korea Uterine Fibroid Treatment Drugs Market Estimates & Forecasts And Trend Analysis, 2018 – 2030 (USD Million)
7.4.6.3 Target Disease Incidence
7.4.6.4 Competitive Scenario
7.4.6.5 Regulatory Framework
7.4.6.6 Reimbursement Scenario
7.4.7 Thailand
7.4.7.1 Key Country Dynamics
7.4.7.2 Thailand Uterine Fibroid Treatment Drugs Market Estimates & Forecasts And Trend Analysis, 2018 – 2030 (USD Million)
7.4.7.3 Target Disease Incidence
7.4.7.4 Competitive Scenario
7.4.7.5 Regulatory Framework
7.4.7.6 Reimbursement Scenario
7.5 Latin America
7.5.1 Latin America Uterine Fibroid Treatment Drugs Market Estimates And Forecasts, 2018 – 2030 (USD Million)
7.5.2 Brazil
7.5.2.1 Key Country Dynamics
7.5.2.2 Brazil Uterine Fibroid Treatment Drugs Market Estimates & Forecasts And Trend Analysis, 2018 – 2030 (USD Million)
7.5.2.3 Target Disease Incidence
7.5.2.4 Competitive Scenario
7.5.2.5 Regulatory Framework
7.5.2.6 Reimbursement Scenario
7.5.3 Mexico
7.5.3.1 Key Country Dynamics
7.5.3.2 Mexico Uterine Fibroid Treatment Drugs Market Estimates & Forecasts And Trend Analysis, 2018 – 2030 (USD Million)
7.5.3.3 Target Disease Incidence
7.5.3.4 Competitive Scenario
7.5.3.5 Regulatory Framework
7.5.3.6 Reimbursement Scenario
7.5.4 Argentina
7.5.4.1 Key Country Dynamics
7.5.4.2 Argentina Uterine Fibroid Treatment Drugs Market Estimates & Forecasts And Trend Analysis, 2018 – 2030 (USD Million)
7.5.4.3 Target Disease Incidence
7.5.4.4 Competitive Scenario
7.5.4.5 Regulatory Framework
7.5.4.6 Reimbursement Scenario
7.6 Middle East And Africa
7.6.1 Middle East And Africa Uterine Fibroid Treatment Drugs Market Estimates And Forecasts, 2018 – 2030 (USD Million)
7.6.1.1 Target Disease Incidence
7.6.1.2 Competitive Scenario
7.6.1.3 Regulatory Framework
7.6.1.4 Reimbursement Scenario
7.6.2 South Africa
7.6.2.1 Key Country Dynamics
7.6.2.2 South Africa Uterine Fibroid Treatment Drugs Market Estimates & Forecasts And Trend Analysis, 2018 – 2030 (USD Million)
7.6.2.3 Target Disease Incidence
7.6.2.4 Competitive Scenario
7.6.2.5 Regulatory Framework
7.6.2.6 Reimbursement Scenario
7.6.3 Saudi Arabia
7.6.3.1 Key Country Dynamics
7.6.3.2 Saudi Arabia Uterine Fibroid Treatment Drugs Market Estimates & Forecasts And Trend Analysis, 2018 – 2030 (USD Million)
7.6.3.3 Target Disease Incidence
7.6.3.4 Competitive Scenario
7.6.3.5 Regulatory Framework
7.6.3.6 Reimbursement Scenario
7.6.4 UAE
7.6.4.1 Key Country Dynamics
7.6.4.2 UAE Uterine Fibroid Treatment Drugs Market Estimates & Forecasts And Trend Analysis, 2018 – 2030 (USD Million)
7.6.4.3 Target Disease Incidence
7.6.4.4 Competitive Scenario
7.6.4.5 Regulatory Framework
7.6.4.6 Reimbursement Scenario
7.6.5 Kuwait
7.6.5.1 Key Country Dynamics
7.6.5.2 Kuwait Uterine Fibroid Treatment Drugs Market Estimates & Forecasts And Trend Analysis, 2018 – 2030 (USD Million)
7.6.5.3 Target Disease Incidence
7.6.5.4 Competitive Scenario
7.6.5.5 Regulatory Framework
7.6.5.6 Reimbursement Scenario
Chapter 8 Competitive Landscape
8.1 Company Market Positioning
8.2 Company Market Share Analysis, 2022
8.3 Company Heat Map Analysis
8.4 Company Profiles
8.4.1 Myovant Sciences Gmbh
8.4.1.1 Company Overview
8.4.1.2 Financial Performance
8.4.1.3 Product Benchmarking
8.4.1.4 Strategic Initiatives
8.4.2 Pfizer Inc.
8.4.2.1 Company Overview
8.4.2.2 Financial Performance
8.4.2.3 Product Benchmarking
8.4.2.4 Strategic Initiatives
8.4.3 Abbvie, Inc.
8.4.3.1 Company Overview
8.4.3.2 Financial Performance
8.4.3.3 Product Benchmarking
8.4.3.4 Strategic Initiatives
8.4.4 Ferring B.V.
8.4.4.1 Company Overview
8.4.4.2 Financial Performance
8.4.4.3 Product Benchmarking
8.4.4.4 Strategic Initiatives
8.4.5 Astrazeneca
8.4.5.1 Company Overview
8.4.5.2 Financial Performance
8.4.5.3 Product Benchmarking
8.4.5.4 Strategic Initiatives
8.4.6 Bayer Ag
8.4.6.1 Company Overview
8.4.6.2 Financial Performance
8.4.6.3 Product Benchmarking
8.4.6.4 Strategic Initiatives
8.4.7 Amring Pharmaceuticals Inc.
8.4.7.1 Company Overview
8.4.7.2 Financial Performance
8.4.7.3 Product Benchmarking
8.4.7.4 Strategic Initiatives
8.4.8 Watson Pharma, Inc.
8.4.8.1 Company overview
8.4.8.2 Financial performance
8.4.8.3 Product benchmarking
8.4.8.4 Strategic initiatives

List of Tables

Table 1 List of Secondary Sources
Table 2 List of Abbreviation
Table 3 Incidence of Diseases
Table 4 Global Uterine Fibroid Treatment Drugs Market, By Region, 2018 - 2030 (USD Million)
Table 5 North America Uterine Fibroid Treatment Drugs Market, By Country, 2018 - 2030 (USD Million)
Table 6 North America Uterine Fibroid Treatment Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 7 North America Uterine Fibroid Treatment Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 8 North America Uterine Fibroid Treatment Drugs Market, By End-User, 2018 - 2030 (USD Million)
Table 9 U.S. Uterine Fibroid Treatment Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 10 U.S. Uterine Fibroid Treatment Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 11 U.S. Uterine Fibroid Treatment Drugs Market, By End-User, 2018 - 2030 (USD Million)
Table 12 Canada Uterine Fibroid Treatment Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 13 Canada Uterine Fibroid Treatment Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 14 Canada Uterine Fibroid Treatment Drugs Market, By End-User, 2018 - 2030 (USD Million)
Table 15 Europe Uterine Fibroid Treatment Drugs Market, By Country, 2018 - 2030 (USD Million)
Table 16 Europe Uterine Fibroid Treatment Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 17 Europe Uterine Fibroid Treatment Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 18 Europe Uterine Fibroid Treatment Drugs Market, By End-User, 2018 - 2030 (USD Million)
Table 19 UK Uterine Fibroid Treatment Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 20 UK Uterine Fibroid Treatment Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 21 UK Uterine Fibroid Treatment Drugs Market, By End-User, 2018 - 2030 (USD Million)
Table 22 Germany Uterine Fibroid Treatment Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 23 Germany Uterine Fibroid Treatment Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 24 Germany Uterine Fibroid Treatment Drugs Market, By End-User, 2018 - 2030 (USD Million)
Table 25 France Uterine Fibroid Treatment Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 26 France Uterine Fibroid Treatment Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 27 France Uterine Fibroid Treatment Drugs Market, By End-User, 2018 - 2030 (USD Million)
Table 28 Italy Uterine Fibroid Treatment Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 29 Italy Uterine Fibroid Treatment Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 30 Italy Uterine Fibroid Treatment Drugs Market, By End-User, 2018 - 2030 (USD Million)
Table 31 Spain Uterine Fibroid Treatment Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 32 Spain Uterine Fibroid Treatment Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 33 Spain Uterine Fibroid Treatment Drugs Market, By End-User, 2018 - 2030 (USD Million)
Table 34 Denmark Uterine Fibroid Treatment Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 35 Denmark Uterine Fibroid Treatment Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 36 Denmark Uterine Fibroid Treatment Drugs Market, By End-User, 2018 - 2030 (USD Million)
Table 37 Sweden Uterine Fibroid Treatment Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 38 Sweden Uterine Fibroid Treatment Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 39 Sweden Uterine Fibroid Treatment Drugs Market, By End-User, 2018 - 2030 (USD Million)
Table 40 Norway Uterine Fibroid Treatment Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 41 Norway Uterine Fibroid Treatment Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 42 Norway Uterine Fibroid Treatment Drugs Market, By End-User, 2018 - 2030 (USD Million)
Table 43 Asia Pacific Uterine Fibroid Treatment Drugs Market, By Country, 2018 - 2030 (USD Million)
Table 44 Asia Pacific Uterine Fibroid Treatment Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 45 Asia Pacific Uterine Fibroid Treatment Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 46 Asia Pacific Uterine Fibroid Treatment Drugs Market, By End-User, 2018 - 2030 (USD Million)
Table 47 Japan Uterine Fibroid Treatment Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 48 Japan Uterine Fibroid Treatment Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 49 Japan Uterine Fibroid Treatment Drugs Market, By End-User, 2018 - 2030 (USD Million)
Table 50 China Uterine Fibroid Treatment Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 51 China Uterine Fibroid Treatment Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 52 China Uterine Fibroid Treatment Drugs Market, By End-User, 2018 - 2030 (USD Million)
Table 53 India Uterine Fibroid Treatment Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 54 India Uterine Fibroid Treatment Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 55 India Uterine Fibroid Treatment Drugs Market, By End-User, 2018 - 2030 (USD Million)
Table 56 Australia Uterine Fibroid Treatment Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 57 Australia Uterine Fibroid Treatment Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 58 Australia Uterine Fibroid Treatment Drugs Market, By End-User, 2018 - 2030 (USD Million)
Table 59 South Korea Uterine Fibroid Treatment Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 60 South Korea Uterine Fibroid Treatment Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 61 South Korea Uterine Fibroid Treatment Drugs Market, By End-User, 2018 - 2030 (USD Million)
Table 62 Thailand Uterine Fibroid Treatment Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 63 Thailand Uterine Fibroid Treatment Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 64 Thailand Uterine Fibroid Treatment Drugs Market, By End-User, 2018 - 2030 (USD Million)
Table 65 Latin America Uterine Fibroid Treatment Drugs Market, By Country, 2018 - 2030 (USD Million)
Table 66 Latin America Uterine Fibroid Treatment Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 67 Latin America Uterine Fibroid Treatment Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 68 Latin America Uterine Fibroid Treatment Drugs Market, By End-User, 2018 - 2030 (USD Million)
Table 69 Brazil Uterine Fibroid Treatment Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 70 Brazil Uterine Fibroid Treatment Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 71 Brazil Uterine Fibroid Treatment Drugs Market, By End-User, 2018 - 2030 (USD Million)
Table 72 Mexico Uterine Fibroid Treatment Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 73 Mexico Uterine Fibroid Treatment Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 74 Mexico Uterine Fibroid Treatment Drugs Market, By End-User, 2018 - 2030 (USD Million)
Table 75 Argentina Uterine Fibroid Treatment Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 76 Argentina Uterine Fibroid Treatment Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 77 Argentina Uterine Fibroid Treatment Drugs Market, By End-User, 2018 - 2030 (USD Million)
Table 78 Middle East & Africa Uterine Fibroid Treatment Drugs Market, By Country, 2018 - 2030 (USD Million)
Table 79 Middle East & Africa Uterine Fibroid Treatment Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 80 Middle East & Africa Uterine Fibroid Treatment Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 81 Middle East & Africa Uterine Fibroid Treatment Drugs Market, By End-User, 2018 - 2030 (USD Million)
Table 82 South Africa Uterine Fibroid Treatment Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 83 South Africa Uterine Fibroid Treatment Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 84 South Africa Uterine Fibroid Treatment Drugs Market, By End-User, 2018 - 2030 (USD Million)
Table 85 Saudi Arabia Uterine Fibroid Treatment Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 86 Saudi Arabia Uterine Fibroid Treatment Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 87 Saudi Arabia Uterine Fibroid Treatment Drugs Market, By End-User, 2018 - 2030 (USD Million)
Table 88 UAE Uterine Fibroid Treatment Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 89 UAE Uterine Fibroid Treatment Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 90 UAE Uterine Fibroid Treatment Drugs Market, By End-User, 2018 - 2030 (USD Million)
Table 91 Kuwait Uterine Fibroid Treatment Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 92 Kuwait Uterine Fibroid Treatment Drugs Market, By Type, 2018 - 2030 (USD Million)
Table 93 Kuwait Uterine Fibroid Treatment Drugs Market, By End-User, 2018 - 2030 (USD Million)

★調査レポート[世界の子宮筋腫治療薬市場2023-2030：薬物クラス別（GnRH作動薬、GnRH拮抗薬）、種類別（粘膜下筋腫、硬膜内筋腫）、エンドユーザー別] (コード：GRV23JUN103)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の子宮筋腫治療薬市場2023-2030：薬物クラス別（GnRH作動薬、GnRH拮抗薬）、種類別（粘膜下筋腫、硬膜内筋腫）、エンドユーザー別]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界の子宮筋腫治療薬市場2023-2030：薬物クラス別（ゴナドトロピン放出ホルモン（GnRH）アゴニスト、ゴナドトロピン放出ホルモン（GnRH）アンタゴニスト、プロゲスチン放出子宮内避妊具（IUD）＆避妊薬、非ホルモン薬、その他）、種類別（漿膜下筋腫、壁内筋腫、粘膜下筋腫、有茎性筋腫）、エンドユーザー別（病院薬局、小売薬局、その他）、地域別
  • 世界のブランドジェネリック市場2023-2030：薬物クラス別（アルキル化剤、代謝拮抗剤、抗高血圧剤）、用途別、投与経路別、流通チャネル別、地域別
  • 世界のピーナッツアレルギー治療市場2023-2030：薬物クラス別（抗ヒスタミン薬、エピネフリン）、投与経路別、流通チャネル別、地域別
  • 世界の抗生物質耐性市場2023-2030：疾患別（cUTI、CDI）、病原体別、薬物クラス別（オキサゾリジノン、リポグリコペプチド）、作用機序別、流通チャネル別、地域別
  • 世界の難聴疾患治療市場2024-2030：製品別（デバイス、薬剤）、疾患タイプ別（伝導性、感音性）、エンドユーザー別（病院、耳科クリニック）、地域別
  • 世界の鎌状赤血球症治療市場2024-2030：治療別（輸血、骨髄移植）、エンドユーザー別（病院、専門クリニック）、地域別

    • ◆H&Iグローバルリサーチのお客様（例）◆